A5074081568- Dermatology and Skin Diseases
- Psoriasis: Treatment and Pathogenesis
- Asthma and respiratory diseases
- Allergic Rhinitis and Sensitization
- Inflammatory Bowel Disease
- Food Allergy and Anaphylaxis Research
- Cytokine Signaling Pathways and Interactions
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Microscopic Colitis
- Cutaneous lymphoproliferative disorders research
- Cancer Immunotherapy and Biomarkers
- Eosinophilic Esophagitis
- Obstructive Sleep Apnea Research
- Immune Cell Function and Interaction
- Statistical Methods in Clinical Trials
- IL-33, ST2, and ILC Pathways
- Monoclonal and Polyclonal Antibodies Research
- Urticaria and Related Conditions
- Gene expression and cancer classification
- Computational Drug Discovery Methods
- CAR-T cell therapy research
- Occupational Health and Performance
- Autoimmune and Inflammatory Disorders
- Autoimmune Bullous Skin Diseases
Icahn School of Medicine at Mount Sinai
2016-2025
New York Proton Center
2013-2025
Mount Sinai Medical Center
2017-2024
Rockefeller University
2012-2023
Center for Information Technology
2020-2023
Harvard University
2023
McGill University
2023
Mount Sinai Hospital
2023
Jewish General Hospital
2023
ENT and Allergy
2023
Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in patients with asthma elevated eosinophil levels. The blockade by dupilumab of these key drivers type 2 helper T-cell (Th2)-mediated inflammation could help the treatment related diseases, including atopic dermatitis.We performed randomized, double-blind, placebo-controlled trials involving adults who had moderate-to-severe dermatitis despite topical glucocorticoids calcineurin...
Background Psoriasis vulgaris is an inflammatory skin disease mediated by Th1 and Th17 cytokines, yet the relative contribution of interferon (IFN)‐γ, interleukin (IL)‐17 IL‐22 on pathogenesis still unknown. Objectives In this study, we sought to identify cytokines produced skin‐resident T cells in normal skin, localize receptors for these examine how alter gene expression profiles bearing cognate receptors. Methods We used intracellular cytokine staining flow cytometry evaluate cell...
Biological agents have dramatically improved treatment options for patients with severe psoriasis. Etanercept (tumor necrosis factor [TNF] receptor-immunoglobulin fusion protein) is an effective many psoriasis patients, and blockade of TNF considered to be its primary action. However, in this clinical trial, we show that etanercept has early inhibitory effects on a newly appreciated type T cells: helper 17 (Th17) cells. reduced the inflammatory dendritic cell products drive Th17...
Dupilumab is an IL-4 receptor α mAb inhibiting signaling of and IL-13, key drivers type 2-driven inflammation, as demonstrated by its efficacy in patients with atopic/allergic diseases.This placebo-controlled, double-blind trial (NCT01979016) evaluated the efficacy, safety, effects dupilumab on molecular/cellular lesional nonlesional skin phenotypes systemic 2 biomarkers moderate-to-severe atopic dermatitis (AD).Skin biopsy specimens blood were from 54 randomized 1:1 to weekly subcutaneous...
BackgroundSevere atopic dermatitis (AD) has a high unmet need for effective and safe therapeutics. In early-phase trials, dupilumab, fully human mAb targeting IL-4 receptor α, markedly improved disease activity, but the effect of IL-4/IL-13 blockade on AD at molecular level not been characterized.ObjectivesWe sought to evaluate dupilumab modulation signature.MethodsWe performed transcriptomic analyses pretreatment posttreatment skin biopsy specimens from patients with moderate-to-severe...
Psoriasis is a complex disease with an expanding definition of its pathological features. We sought to expand/refine the psoriasis transcriptome using 85 paired lesional and non-lesional samples from cohort patients moderate-to-severe vulgaris who were not receiving active therapy. This new analysis identified 4,175 probe sets (representing 2,725 unique known genes) as being differentially expressed in lesions compared matched biopsies skin when following criteria applied: >2-fold change...
Abstract Beyond classic “allergic”/atopic comorbidities, atopic dermatitis (AD) emerges as systemic disease with increased cardiovascular risk. To better define serum inflammatory and risk proteins, we used an OLINK high-throughput proteomic assay to analyze moderate-to-severe AD (n = 59) compared psoriasis 22) healthy controls 18). Compared controls, 10 proteins were in of both diseases, including Th1 (IFN-γ, CXCL9, TNF-β) Th17 (CCL20) markers. 48 each uniquely upregulated psoriasis....
Atopic dermatitis (AD) is the most common inflammatory skin disease, but treatment options for moderate-to-severe disease are limited. Ustekinumab an IL-12/IL-23p40 antagonist that suppresses Th1, Th17 and Th22 activation, commonly used psoriasis patients. We sought to assess efficacy safety of ustekinumab in patients with AD. In this phase II, double-blind, placebo-controlled study, 33 AD were randomly assigned either (n=16) or placebo (n=17), subsequent crossover at 16 weeks, last dose 32...